Levocarnitine acetyl stimulates peripheral nerve regeneration and neuromuscular junction remodelling following sciatic nerve injury.
The effects of levocarnitine acetyl were investigated on both peripheral nerve regeneration and neuromuscular remodelling in male Sprague-Dawley rats, three months of age, following crush of their left sciatic nerve. Levocarnitine acetyl, 150 mg/kg/day in drinking water, was given from one week before to 5, 15, 20, and 60 days after nerve crush. The sciatic nerve was examined morphologically at all given times and morphometrically at 15, 20, and 60 days after the lesion. Morphology, at 5, 15, and 60 days, and morphometry, at 60 days after the nerve crush, were also performed on the neuromuscular junction in the soleus and extensor digitorum longus muscles. Five days after nerve crush, complete axonal degeneration was observed in both control and treated rats. At 15 and 20 days, recovery from injury in treated animals was better than in controls, as shown by a significantly higher increase in the number of regenerating axons. At the same times, denervated endplates were present in both groups. At 60 days, axonal regeneration restored the number of axons to normal values in all injured animals, while their size maturation was greater in treated rats than in controls. A markedly lower number of degenerating elements was found in treated animals. In the neuromuscular junctions of the soleus and extensor digitorum longus muscles, nerve terminal branch points were reduced in the lesioned rats in comparison with uninjured ones. However, morphometric analysis revealed a greater endplate complexity in treated animals in which, at 60 days after nerve crush, nerve terminal branching and sprouting index values were significantly higher than in controls. It is concluded that levocarnitine acetyl exerts a beneficial effect on nerve regeneration processes and synaptic remodelling in crush-induced neuropathies.
De Angelis
C
C
Institute for Research on Senescence, Sigma Tau S.p.A., Pomezia, Rome, Italy.
Scarfò
C
C
Falcinelli
M
M
Reda
E
E
Ramacci
M T
MT
Angelucci
L
L
D000108:Acetylcarnitine / Q000494:pharmacology*; D000818:Animals; D008297:Male; D009409:Nerve Crush; D009410:Nerve Degeneration; D009416:Nerve Regeneration / Q000187:drug effects*; D009469:Neuromuscular Junction / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D009473:Neuronal Plasticity / Q000187:drug effects; D010525:Peripheral Nerves / Q000187:drug effects* / Q000502:physiology; D010523:Peripheral Nervous System Diseases / Q000473:pathology / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve; D013979:Tibial Nerve / Q000187:drug effects / Q000473:pathology / Q000502:physiology
D000108:Acetylcarnitine